Formula Growth
CADL icon

Formula Growth’s Candel Therapeutics CADL Stock Holding History

Formula Growth’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.1M Buy
+105,000
New +$1.16M 0.42% 92

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Kennedy Capital Management
Kennedy Capital Management St Louis, Missouri $5.31B AUM 40.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return

Formula Growth's CADL Position: Q3 2026 in Review

Formula Growth opened a new position in Candel Therapeutics (CADL) in Q3 2026: 105,000 shares worth $1.1M. The stake represents 0.42% of the portfolio and ranks #92 among its holdings.

106 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Formula Growth held 105,000 shares of Candel Therapeutics worth $1.1M as of Q3 2026.
  • Candel Therapeutics was a new Formula Growth position in Q3 2026.
  • Candel Therapeutics made up 0.42% of Formula Growth's portfolio in Q3 2026, its #92 holding.
  • 106 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Formula Growth's 13F filing for Q3 2026, filed 13 Nov 2026.